摘要
Dear Editor,Breast cancer(BC)is the most commonly diagnosed cancer and the fifth cause of cancer-related death worldwide[1].Despite the advances in BC targeted therapies,cytotoxic chemotherapy is still widely used[2].However,around 20%-30%of BC patients develop metastasis after treatment as a consequence of drug resistance[3].In this context,microRNAs have emerged as potential therapeutic targets to overcome therapy resistance[4].Therefore,we aimed to elucidate the molecular mechanisms underlying resistance to doxorubicin,one of the most effective chemotherapeutic agents used in BC.Methods are detailed in Supplementary Materials.
基金
supported by Spanish Government and cofinanced by FEDER Funds(PI18/01219,PI21/01351,PI18/00382,and RTI2018-100910-B-C41)
CIBERBBN(CB07/01/2012)
CIBERONC(CB16/12/00481)
the Generalitat Valenciana(project PROMETEO 2018/024)
funded by Generalitat Valenciana(ACIF/2016/030)
funded by Asociación Española Contra el Cancer.
funded by Instituto de Salud Carlos Ⅲ and the European Social Fund for the financial support“Sara Borrell”(CD19/00038)
funded by Ministerio de Ciencia e Innovación(FPU grant)
funded by Sociedad Española de Oncología Médica(Río Hortega-SEOM).